168 related articles for article (PubMed ID: 32601264)
41. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
42. p53 Dysregulation in Breast Cancer: Insights on Mutations in the
Steffens Reinhardt L; Groen K; Xavier A; Avery-Kiejda KA
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373225
[TBL] [Abstract][Full Text] [Related]
43. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
[TBL] [Abstract][Full Text] [Related]
44.
Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
[TBL] [Abstract][Full Text] [Related]
45. Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity.
Fischer NW; Prodeus A; Gariépy J
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089713
[TBL] [Abstract][Full Text] [Related]
46. Validation of p53 Immunohistochemistry (PAb240 Clone) in Canine Tumors with Next-Generation Sequencing (NGS) Analysis.
Brunetti B; de Biase D; Dellapina G; Muscatello LV; Ingravalle F; Tura G; Bacci B
Animals (Basel); 2023 Mar; 13(5):. PubMed ID: 36899756
[TBL] [Abstract][Full Text] [Related]
47. Analysis of full coding sequence of the TP53 gene in invasive vulvar cancers: Implications for therapy.
Kashofer K; Regauer S
Gynecol Oncol; 2017 Aug; 146(2):314-318. PubMed ID: 28527674
[TBL] [Abstract][Full Text] [Related]
48. Correlation of TP53 mutations and p53 expression in ovarian tumors.
DiCioccio RA; Werness BA; Peng R; Allen HJ; Piver MS
Cancer Genet Cytogenet; 1998 Sep; 105(2):93-102. PubMed ID: 9723023
[TBL] [Abstract][Full Text] [Related]
49. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
[TBL] [Abstract][Full Text] [Related]
50. Prognostic implications and interaction of L1 methylation and p53 expression statuses in advanced gastric cancer.
Shin YJ; Kim Y; Wen X; Cho NY; Lee S; Kim WH; Kang GH
Clin Epigenetics; 2019 May; 11(1):77. PubMed ID: 31088544
[TBL] [Abstract][Full Text] [Related]
51. Redefining aberrant P53 expression of gastric cancer and its distinct clinical significance among molecular-histologic subtypes.
Huang SC; Chang IY; Chen TC; Lin HC; Tsai CY; Hsu JT; Yeh CN; Chang SC; Yeh TS
Asian J Surg; 2024 Jun; ():. PubMed ID: 38845323
[TBL] [Abstract][Full Text] [Related]
52. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
53. Role of p53 in the progression of gastric cancer.
Busuttil RA; Zapparoli GV; Haupt S; Fennell C; Wong SQ; Pang JM; Takeno EA; Mitchell C; Di Costanzo N; Fox S; Haupt Y; Dobrovic A; Boussioutas A
Oncotarget; 2014 Dec; 5(23):12016-26. PubMed ID: 25427447
[TBL] [Abstract][Full Text] [Related]
54. DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications.
Klumb CE; Furtado DR; de Resende LM; Carriço MK; Coelho AM; de Meis E; Maia RC; Rumjanek FD
Eur J Haematol; 2003 Aug; 71(2):81-90. PubMed ID: 12890146
[TBL] [Abstract][Full Text] [Related]
55. Different mutation profiles associated to P53 accumulation in colorectal cancer.
López I; P Oliveira L; Tucci P; Alvarez-Valín F; A Coudry R; Marín M
Gene; 2012 May; 499(1):81-7. PubMed ID: 22373952
[TBL] [Abstract][Full Text] [Related]
56. Initial and crucial genetic events in intestinal-type gastric intramucosal neoplasia.
Rokutan H; Abe H; Nakamura H; Ushiku T; Arakawa E; Hosoda F; Yachida S; Tsuji Y; Fujishiro M; Koike K; Totoki Y; Fukayama M; Shibata T
J Pathol; 2019 Apr; 247(4):494-504. PubMed ID: 30474112
[TBL] [Abstract][Full Text] [Related]
57. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
58. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.
Ozcelik H; Pinnaduwage D; Bull SB; Andrulis IL
Breast Cancer Res Treat; 2007 Nov; 105(3):255-65. PubMed ID: 17221157
[TBL] [Abstract][Full Text] [Related]
59. Non-disruptive mutation in
Huang M; Jin J; Zhang F; Wu Y; Xu C; Ying L; Su D
Ann Transl Med; 2020 Mar; 8(6):316. PubMed ID: 32355760
[TBL] [Abstract][Full Text] [Related]
60. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
